Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CASM regulates lysosomal expansion and cell fate during senescence
Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel
Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel
View: Text | PDF
Research Article Aging Cell biology

CASM regulates lysosomal expansion and cell fate during senescence

  • Text
  • PDF
Abstract

Cellular senescence, a hallmark of aging, is accompanied by a striking expansion of the cell’s lysosomal compartment, yet the pathway leading to increased lysosomal content remains unresolved. Here, we demonstrate that the master lysosomal transcriptional regulator TFEB is activated during senescence through a pathway that involves conjugation of ATG8 onto single membranes (CASM). Using various senescence inducers, we show that senescence induction triggers robust TFEB nuclear translocation and upregulation of TFEB target genes. In contrast, inhibition of the core CASM machinery by CRISPR-mediated deletion of either ATG16L1, ATG12, or ATG5 markedly reduced senescence-induced TFEB nuclear translocation. In ATG16L1-KO cells, reconstitution with WT ATG16L1 but not the CASM-defective ATG16L1F467A mutant restored both ATG8 lipidation on the lysosomal surface and TFEB activation. Moreover, expression of the Salmonella effector protein SopF, a previously described specific CASM inhibitor, similarly blocked senescence-induced TFEB translocation. Functionally, upon stress, CASM-deficient cells exhibited a pronounced shift away from senescence and toward a cell death fate, a phenotype reversed by expressing a constitutively active form of TFEB. Together, these findings identify CASM-dependent TFEB activation as an essential mechanism enabling senescence-associated lysosomal expansion and suggest that lysosomal capacity modulates cell fate decisions in the aftermath of acute stress.

Authors

Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel

×

Figure 4

Blocking CASM shifts the cell fate decision from senescence to cell death.

Options: View larger image (or click on image) Download as PowerPoint
Blocking CASM shifts the cell fate decision from senescence to cell deat...
(A) Cell death analysis by annexin V/propidium iodide (PI) staining and flow cytometry of WT and CASM-deficient KO BEAS-2B cells before and 3 days after senescence induction with 100 nM DOX. Flow cytometry plots are representative of n = 3 independent experiments. (B) Quantification of viability in WT and CASM-deficient knockout cells before and after senescence induction. Mean ± SD; statistical significance was determined by 1-way ANOVA followed by Dunnett’s multiple-comparison test against WT. (C) Quantification of viability in WT and CASM-deficient KO cells before and after 100 nM staurosporine treatment. Mean ± SD; statistical significance was determined by 1-way ANOVA followed by Dunnett’s multiple-comparison test against WT. (D) Quantification of viability in WT, ATG16L1-KO, or ATG16L1-KO cells reconstituted with ATG16L1WT or CASM-defective ATG16L1F467A. Data are mean ± SD; significance by 1-way ANOVA with Šídák’s multiple-comparison test on the prespecified comparisons of interest. (E) Quantification of viability in WT and SopF-expressing BEAS-2B cells before and 3 days after senescence induction. Data are mean ± SD; statistical significance was determined by a 2-tailed unpaired t test with Welch’s correction. (F) Quantification of viability in WT and ATG13-KO BEAS-2B cells before and 3 days after senescence induction. Data are mean ± SD; statistical significance was determined by a 2-tailed unpaired t test with Welch’s correction. (G) LysoIP immunoblot of LC3-II from control or senescent (Day 3) WT and ATG16L1-KO BJ fibroblasts expressing TMEM192-3xHA. β-Actin and ATG16L1 serve as loading controls. Blots are representative of n = 3 independent experiments. (H) Quantification of viability in WT and ATG16L1-KO BJ fibroblasts before and 3 days after senescence induction with 5 μM Bleo. Data are mean ± SD; significance by 2-tailed unpaired t test with Welch’s correction. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts